Daniel M. Whalen - Concepedia

Author

Daniel M. Whalen

Also Known As

D. Whalen, D.M. Whalen, DANIEL WHALEN, Daniel M Whalen, Daniel M. Whalen, Daniel Whalen, Daniel M. Whalen, Stanley, Nathaniel, Whalen, Daniel M

Publications

Citations

H-Index

Concepts

All Affiliations

Revolution Medicines (United States)Centre for Human Genetics University of Oxford Washington University in St. Louis

About

Daniel M. Whalen is an author at Revolution Medicines (United States) specializing in medicine, tumor biology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	263
2	Cell Biology	3	3	52
3	Engineering	1	1	16
4	Biomolecular Engineering	1	1	16
5	Molecular Biology	1	1	13

Daniel M. Whalen

Publications

927

Citations

H-Index

Page 1

	Year	Citations
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2 Scott A. Foster, Daniel M. Whalen, Ayşegül Özen, Cancer Cell Developmental BiologyOncogenic Deletion MutationsCell RegulationGeneticsGenomic Mechanism	2016	211
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao, Science	2023	203
Structure and function of the Smoothened extracellular domain in vertebrate Hedgehog signaling Sigrid Nachtergaele, Daniel M. Whalen, Laurel K. Mydock, eLife	2013	163
Vaccinia Virus Proteins A52 and B14 Share a Bcl-2–Like Fold but Have Evolved to Inhibit NF-κB rather than Apoptosis Stephen C. Graham, Mohammad W. Bahar, Samantha Cooray, PLoS Pathogens	2008	151
Structural insights into proteoglycan-shaped Hedgehog signaling Daniel M. Whalen, Tomas Malinauskas, Robert J.C. Gilbert, Proceedings of the National Academy of Sciences	2013	104
Kinase domain dimerization drives RIPK3-dependent necroptosis Saravanan Raju, Daniel M. Whalen, Meron Mengistu, Science Signaling	2018	43
A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC R. Jeremy Nichols, Chris J. Schulze, Alun Bermingham, Journal of Thoracic Oncology Gtp-bound FormDrive Tumor RegressionsOncogenic AgentReceptor Tyrosine KinaseA06 Tri-complex Inhibitors	2020	23
Abstract PR10: Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions <i>in vivo</i> Christopher J. Schulze, Alun Bermingham, Tiffany J. Choy, Molecular Cancer Therapeutics A Kras MutationEngineeringCancer BiologyGtp-bound FormTumor Biology	2019	16
Abstract 1261: A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibition Robert J. Nichols, Jim Cregg, Christopher J. Schulze, Cancer Research Molecular BiologyCancer BiologyTumor BiologyAbstract 1261Activate Krasg12c	2021	13

Page 1